930093-72-4

Usage

Uses

Used in Pharmaceutical Industry:
4-Chloro-5-methyl-6-(2-methylpyridin-3-yloxy)pyrimidine is used as a building block in the synthesis of various pharmaceutical compounds. Its unique chemical structure allows it to be a key component in the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In addition to its pharmaceutical applications, 4-Chloro-5-methyl-6-(2-methylpyridin-3-yloxy)pyrimidine is also utilized as a building block in the synthesis of agrochemicals. Its incorporation into these products can contribute to the development of effective solutions for agricultural challenges.

Upstream product

• 1121-25-1 2-methyl-3-pyridinol 
• 4316-97-6 4,6-dichloro-5-methylpyrimidine 

Downstream Products

• 1147553-19-2 C₂₅H₂₈N₄O₂ 
• 1233322-62-7 C₂₄H₂₅FN₄O₂ 
• 1147552-28-0 C₂₄H₂₅FN₄O₄S 

Relevant academic research and scientific papers

Design and synthesis of diazatricyclodecane agonists of the G-protein-coupled receptor 119

A series of GPR119 agonists based on a 2,6-diazatricyclo[3.3.1.1～3, 7～]decane ring system is described. Also provided is a detailed account of the development of a multigram scale synthesis of the diazatricyclic ring system, which was achieved using a Hofmann-L?ffler-Freytag reaction as the key step. The basis for the use of this complex framework lies in an attempt to constrain one end of the molecule in the agonist conformation as was previously described for 3-oxa-7-aza-bicyclo[3.3.1]nonanes. Optimization of carbamate analogues of the diazatricylic compounds led to the identification of 32i as a potent agonist of the GPR119 receptor with low unbound human liver microsomal clearance. The use of an agonist response weighted ligand lipophilic efficiency (LLE) termed AgLLE is discussed along with the issues of applying efficiency measures to agonist programs. Ultimately, solubility limited absorption and poor exposure reduced further interest in these molecules.

Discovery of a nortropanol derivative as a potent and orally active GPR119 agonist for type 2 diabetes

The lead optimization studies of a series of GPR119 agonists incorporating a nortropanol scaffold are described. Extensive structure-activity relationship (SAR) studies of the lead compound 20f led to the identification of compound 36j as a potent, single digit nanomolar GPR119 agonist with high agonist activity. Compound 36j was orally active in lowering blood glucose levels in a mouse oral glucose tolerance test and increased plasma insulin levels in a rat hyperglycemic model. It showed good to excellent pharmacokinetic properties in rats and monkeys and no untoward activities in counter-screen assays. Compound 36j demonstrated an attractive in vitro and in vivo profile for further development.

BICYCLIC PIPERIDINE AND PIPERAZINE DERIVATIVES AS GPCR MODULATORS FOR THE TREATMENT OF OBESITY, DIABETES AND OTHER METABOLIC DISORDERS

The present invention relates to Bicyclic Piperidine and Piperazine Derivatives, compositions comprising a Bicyclic Piperidine and Piperazine Derivative, and methods of using the Bicyclic Piperidine and Piperazine Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of a GPCR in a patient.

MODULATORS OF METABOLISM AND THE TREATMENT OF DISORDERS RELATED THERETO

The present invention relates to 4-[5-methyl-6-(2-methyl-pyridin-3-yloxy)-pyrimidin-4-yloxy]-piperidine-1-carboxylic acid isopropyl ester, pharmaceutically acceptable salts, solvates and hydrates thereof that are modulators of glucose metabolism. Accordingly, compounds of the present invention are useful in the treatment of metabolic-related disorders and complications thereof, such as, diabetes and obesity.